Treatment patterns and clinical characteristics of patients with type 2 diabetes mellitus according to body mass index: findings from an electronic medical records database

Wayne Weng,1 Ye Tian,1 Edward S. Kimball,2 Sheldon X. Kong,1 Jonathan Bouchard,1 Todd M. Hobbs,3 Brian Sakurada4

ABSTRACT

Objective This study evaluated relationships between glycaemic control, body mass index (BMI), comorbidities and pharmacological treatment in patients with type 2 diabetes mellitus (T2D).

Research design and methods This was a retrospective, cross-sectional analysis of Quintiles electronic medical records research data (study period 1 October 2013–30 September 2014). Eligibility included age ≥18 years, T2D diagnosis, and at least one available BMI measurement.

Results The study included 626,386 patients (mean age, 63.8 year; 51.3% female; 78.5% white; 62.6%, BMI >30 kg/m²). A1c data were available for 414,266 patients. The proportion of patients with good glycaemic control (A1c <6.5) decreased as BMI category increased, ranging from 40.1% of patients with BMI <30 to 30.1% of patients with BMI ≥40. The proportions of patients with poor glycaemic control (A1c >8% and A1c ≥9%) increased with increasing BMI category. Oral antidiabetic drugs (OAD) were the most frequently used (54.4% of patients with A1c values). Among patients using insulin-based therapy, 50% had an A1c ≥8% and 29% had an A1c ≥9% regardless of concomitant OAD or glucagon-like peptide 1 receptor agonist use. Among patients using three or more OADs, 34.3% and 16.1% had A1c values ≥8% and ≥9%, respectively. There was no common trend observed for changes in the proportion of patients with T2D-related comorbidities according to BMI category. The most notable trend was a 7.6% net increase in the percentage of patients with hypertension from BMI <30 to BMI ≥40.

Conclusions This large dataset provides evidence that roughly one out of four patients with T2D is not well controlled, and the prevalence of poor glycaemic control increases as BMI increases.

INTRODUCTION

The epidemic of type 2 diabetes mellitus (T2D) is increasing worldwide resulting in increased health burden and reductions in life expectancy. This epidemic is considered to partly be fueled by an increase in obesity rates, which has long been recognized as playing a role in the pathogenesis of T2D.1,2 Approximately 80% of patients with T2D are either overweight or obese.3 Effective treatment strategy to achieve good glycaemic control, as measured via hemoglobin A1c (A1c), is essential and has been well documented to correlate with the development of microvascular and macrovascular complications of T2D.4 Diabetes mellitus management using pharmacological treatments has become increasingly complex with the variety of agents and treatment guidelines available.3,5,6 Despite extensive treatment guidelines and a wide array of treatment options from the American Diabetes Association (ADA), the European Association for
| Total (n) (%) | BMI category | All | <30 | 30–<35 | 35–<40 | ≥40 |
|--------------|--------------|-----|-----|--------|--------|-----|
| 626 386 100  | 234 236 37.4 | 177 476 | 18.3 | 113 223 | 16.1 | 101 451 |
| BMI (kg/m²)  | Mean 33.2    | 26.3 | 32.4 | 37.2   | 45.8   |     |
| SD           | 7.4 2.7      | 1.4  | 1.4  | 5.4    |        |     |
| Age (year)   | Mean 63.8    | 67.2 | 64   | 61.5   | 58.1   |     |
| SD           | 12.1 11.8    | 11.5 | 11.7 | 11.8   |        |     |
| Age group, year (%)† | 18–44 7.2 | 4.7  | 5.9  | 8.5    | 13.8   |     |
|              | 45–64 41.1   | 31.5 | 41.9 | 48.0   | 54.1   |     |
| ≥65          | 51.7 63.8    | 52.2 | 43.5 | 32.1   |        |     |
| Gender (%)†  | Female 51.3  | 48.2 | 47.5 | 53.5   | 63.0   |     |
|              | Male 48.7    | 51.8 | 52.5 | 46.5   | 37.0   |     |
| Race (%)†    | Black 13.9   | 12.7 | 13.4 | 14.4   | 16.7   |     |
|              | Other 7.7    | 10.3 | 7.0  | 5.8    | 5.0    |     |
|              | White 78.5   | 77.1 | 79.6 | 79.8   | 78.3   |     |
| Region (%)†  | Midwest 19.3 | 17.1 | 19.1 | 20.7   | 23.2   |     |
|              | Northeast 23.6 | 23.6 | 24.0 | 23.6   | 22.9   |     |
|              | South 41.1   | 42.9 | 41.0 | 40.1   | 38.6   |     |
|              | West 16.0    | 16.4 | 15.9 | 15.6   | 15.4   |     |
| Insurance (%)† | Commercial 19.4 | 16.0 | 20.1 | 22.3   | 23.0   |     |
|              | Medicaid 1.4 | 1.1  | 1.2  | 1.5    | 2.3    |     |
|              | Medicare 39.1 | 45.7 | 38.3 | 34.3   | 30.3   |     |
|              | Other/Unknown 37.4 | 34.6 | 37.6 | 39.1   | 41.6   |     |
|              | Self-pay 2.8 | 2.7  | 2.8  | 2.8    | 2.9    |     |
| Mean (SD) A1c, (%) | 7.2 (1.5) | 7.4 (1.5) | 7.5 (1.6) | 7.5 (1.6) |     |

*Percent of total subjects.
†Percent of subjects in respective BMI categories.
BMI, body mass index; SD, standard deviations; T2D, type 2 diabetes mellitus.
the Study of Diabetes (EASD) and the National Institute for Health and Care Excellence, the proportion of patients with T2D achieving good glucose control has not increased greatly since 2008.

Limited real-world data are currently available that evaluate obesity prevalence according to BMI and glycaemic control via HbA1c values among patients with T2D and how this relates to treatment patterns and comorbidities. This study used a large electronic medical records (EMR) database to evaluate relationships between glycaemic control, BMI, comorbidities and pharmacological T2D treatment.

**RESEARCH DESIGN AND METHODS**

**Data source**

The Quintiles EMR (Q-EMR) research database was the data source for this study. The Q-EMR database includes patient-level ambulatory medical records from approximately 35 million patients throughout the USA, captured with the GE Centricity user interface. This database contains data covering patient vital signs and laboratory results that include BMI and A1c values.

**Study design and subjects**

This was a retrospective, cross-sectional analysis of adults during the study period between 1 October 2013 and 30 September 2014. Inclusion criteria were age ≥18 years, medical record activity during the study period, at least one recorded BMI measurement during the study period; and a diagnosis of T2D according to a record of at least one International Classification of Diseases Ninth Revision (ICD-9) code of 250.x0 or 250.x2.

Individuals with Type 1 Diabetes were excluded (ICD-9 codes 250.x1 or 250.x3). Also excluded were individuals with comorbidities that were known to cause excessive weight changes. These included malignancy, HIV, cachexia, anorexia, abnormal weight gain or loss, feeding difficulties, gastrointestinal disorders that result in intestinal malabsorption, including celiac disease, inflammatory bowel disease, acute and chronic pancreatitis, non-vitamin-related nutritional deficiencies, pregnancy, Cushing’s syndrome and severe psychiatric disorders.

**Analysis**

Demographic characteristics, A1c values, T2D-related comorbidities and antidiabetic medication use were stratified and evaluated in relationship to BMI category. For patients who had more than one BMI measurement during the study period, the calculated mean of all available BMI values was used for analysis. Patients were grouped according to BMI category (<30, 30–<35, 35–<40 and ≥40 kg/m²) and age group (18–44, 45–64 and >65 years). T2D-related medications were grouped per medication class: oral antidiabetes drugs (OADs), glucagon-like peptide 1 receptor agonists (GLP-1 RA) and insulins.

Glycaemic control was assessed as each patient’s latest available A1c measurement during the study period. For Table 2

| Drug class for patients with A1c measurements | A1c ≥9% | n | %* | n | %* |
|----------------------------------------------|--------|---|----|---|----|
| All with A1c data | Total | 414,266 | 103,447 | 25.0 | 55,454 | 13.4 |
| No drugs | OAD only | 225,156 | 36,943 | 16.4 | 16,746 | 7.4 |
| 1 OAD | 120,784 | 9,273 | 7.7 | 3,743 | 3.1 |
| 2 OADs | 74,329 | 17,379 | 23.4 | 8,176 | 11.0 |
| 3+OADs | 30,043 | 10,291 | 34.3 | 4,827 | 16.1 |
| Insulin, w/wo OAD | 112,111 | 55,668 | 49.7 | 32,998 | 29.4 |
| GLP-1 RA, w/wo OAD | 12,477 | 3,397 | 27.2 | 3,821 | 29.4 |

Category of A1c ≥9% reflects all patients at or over this cut-off (including ≥9%). % values reflect % across rows, with ‘All with A1c data’ column as the denominator.

GLP-1 RA glucagon-like peptide 1 receptor agonist; OAD, oral antidiabetes drug; w/wo, with or without.
Obesity Studies

analysis purposes, A1c findings were grouped into categories of ≤6.5%, >6.5%–<8%, ≥8%, and ≥9%. As an A1c measurement, ≥8% is considered a lower limit of poor glycaemic control, patient BMI distributions within the categories of A1c ≥8% and ≥9% was more closely examined to ascertain if a relationship between glycaemic control, BMI, and treatment modality could be observed.

For each patient, a Diabetes Complications Severity Index (DCSI) was determined and mean values for each BMI category were computed. The DCSI was designed to model the severity of diabetes mellitus complications at any given time point and is a useful tool for predicting mortality and risk of hospitalisation. The index factors in the following categories of complications: cardiovascular disease, nephropathy, retinopathy, peripheral vascular disease, stroke, neuropathy and metabolic.

No statistical tests for differences were used to differentiate among patients in the four BMI categories, as the analysis was intended to be an exploratory analysis and because the large sample size could make even minor differences appear to be statistically significant.

Figure 1  Categorical A1c distribution within BMI categories, n=414,266 patients with T2D and available A1c data. % values represent percentage of subjects within each BMI category having an A1c value within the categorical range. Category of A1c ≥8% reflects all patients at or over this cut-off (including ≥9%). BMI, body mass index; T2D, type 2 diabetes mellitus.

Figure 2  Distribution of T2D medication class users with each BMI category. *With or without OAD. †Median number of OADs used=1, regardless of BMI. BMI, body mass index; GLP-1 RA, glucagon-like peptide 1 receptor agonist; OAD, oral antidiabetes drug; T2D, type 2 diabetes mellitus; w/wo, with or without.
RESULTS

Patient demographics and BMI distribution patterns

The study population included 626,386 patients (table 1). Approximately half of the population (51.7%) was ≥65 years of age, and only 7.2% were 44 years of age or younger. The majority (78.5%) of patients were white, and the largest geographic region represented was the South (41.1%). By BMI category, 37.4% of patients with T2D had a BMI <30 kg/m², whereas the remaining 62.6% had a BMI ≥30 kg/m², qualifying as obese according to National Heart, Lung, and Blood Institute (NHLBI) definitions. Furthermore, 16.2% of patients with T2D had a BMI ≥40, a category classified by NHLBI as ‘extreme obesity’.

Mean patient age decreased as BMI category increased, and the percentage of females increased with increasing BMI category. Black patients with T2D comprised 13.9% of all patients with T2D. Their proportions increased with higher BMI category to 16.7% of those with BMI ≥40. In comparison, white patients with T2D comprised 78.5% of all patients with T2D, but there was a lower proportion of white patients with BMI ≥40 compared with the next two lower BMI categories, BMI 30–<35 and 35–<40, which had moderately higher proportions. Patients with T2D using commercial insurance increased as a proportion of those with insurance as BMI category increased, whereas patients with Medicare decreased from 45% of those with BMI <30 to 30.3% of those with BMI ≥40.

Relationship between antidiabetes medication use, BMI and A1c

A1c data were available for 414,266 (66.2%) of the total 626,386 patients with T2D in the study. Among all patients with A1c data, 25.0% (n=103,447) had an A1c ≥8% and 13.4% (n=55,454) had an A1c ≥9% (table 2). Among patients using two OADs, 23.4% had an A1c ≥8% and 11.0% had an A1c ≥9%. Among patients using three or more OADs, 34.3% and 16.1% had A1c values ≥8% and ≥9%, respectively. The status of glycaemic control was even worse among patients using insulin-based therapy; among these patients 50% had an A1c ≥8% and 29% had an A1c ≥9% regardless of concomitant OAD or GLP-1 RA use.

The BMI ≥30 subgroup had the largest proportion of patients with A1c ≤6.5% (40.1%) and the proportion of patients in this category of good glycaemic control decreased as BMI category increased (figure 1). Conversely, the proportions of patients with poor glycaemic control (A1c ≥8% and A1c ≥9%) increased with increasing BMI category. The proportions of patients with A1c values >6.5%–<8% within each BMI category were similar and ranged from 38.9% to 40.2%.

Figure 2 shows the distribution of antidiabetes medication classes among BMI categories for all patients. The BMI <30 category had the largest proportion of patients who used no drugs (17.7%). The proportion of OAD-only users decreased as BMI category increased. The median number of OADs used in each BMI category was 1. Conversely, insulin and GLP-1 RA use increased with increasing BMI category. Insulin use (alone and with a GLP-RA, both with or without OADs) was reported in 25.6% of patients with BMI <30; this proportion increased to 29.3%, 33.4% and 37.4% among patients with BMIs ≥30, ≥35, and ≥40, respectively. GLP-1 RA use (alone and with insulin, both with or without OADs) was reported in 2.7%, 5.7%, 7.8% and 9.8% of patients with BMIs <30, 30–<35, 35–<40 and ≥40, respectively.
Relationship between T2D-related comorbidities and BMI

There was no common trend observed for changes in the proportion of patients with T2D-related comorbidities according to BMI category (figure 3). The proportion of patients with hypertension increased a net 7.6% from BMI <30 to BMI ≥40, but only 2.9% for neuropathy. There were small decreases in the proportions of patients with hyperlipidemia, nephropathy and peripheral vascular disease (ranging from −2.7 to −3.9%), and slightly larger decreases for the proportion of patients with cardiovascular and cerebrovascular disease (−8.6 and −5.6%, respectively) as BMI category increased. The proportion of patients with retinopathy was little changed (−0.9% across all BMI categories). Mean DCSI scores were slightly higher (1.4) for the BMI <30 category, decreasing to 1.1 for the BMI <40 category.

CONCLUSIONS

This study examined data of patients with T2D in a large EMR database to evaluate BMI and potential relationships with comorbidities, medication usage, and A1c status. To our knowledge, the current dataset represents one of the largest to date to have evaluated BMI and clinical and treatment characteristics in patients with T2D, with a total population of 626,386 patients, 414,266 of whom had A1c values available for analysis. This study is also the only large US study of its kind based on EMR data, which affords a unique and accurate means of capturing actual patient BMI data as well as clinical benchmark variables such as A1c. The Quintiles EMR research database (previously GE Centricity database) is a commercially available, high-quality source of anonymized medical records that is well recognised for its value in outcomes research.15–18 EMR data has been shown to be highly more accurate for capturing BMI status than claims data.19

The current analysis confirmed a high rate of obesity among patients in the USA with T2D. Approximately two-thirds (62.6%) of the current study population with T2D were classified as obese (BMI ≥30 kg/m²). Our study did not include a control group without T2D, but according to data from the National Health and Nutrition Examination Survey (NHANES; 1999–2006),20,21 the prevalence of obesity in the USA is estimated at about one-third of the general population. Furthermore, the prevalence of extreme obesity (BMI ≥40) in the current study was an alarming 16%, or about one in six patients, while NHANES data estimate the prevalence of extreme obesity to be approximately 5% in the general population. Thus, based on an indirect comparison of NHANES data and the current EMR data, the prevalence of obesity appears to be roughly doubled among individuals with T2D, and that of extreme obesity possibly three times higher. NHANES data from the period 1999–2006 also noted a prevalence of obesity (BMI ≥30) in 49% of patients with diabetes mellitus, which is lower than that noted in our EMR analysis. The reasons for this discrepancy are not clear. In the NHANES survey, BMI values are noted on actual height and weight assessments, as are the EMR data. However, it is worth noting that the size of the T2D population in the current dataset was substantially larger than that in the NHANES report (626,386 vs 2,894).

As a surrogate marker of glycaemic control, A1c levels reflect average glycaemia over several months (3) and have been shown to be strongly predictive for the risk of diabetes mellitus complications.1,22 The ADA recommends A1c testing at a minimum of twice a year in patients who are meeting treatment goals, and quarterly if therapy is being changed and/or goals are not being met.23

Among patients in the current study with available A1c values, poor glycaemic control, defined as A1c ≥8%, was evident in 25% of patients, which is nearly identical to findings from the NHANES survey (23%; 1999–2006 data).24 Moreover, in this study, 13% of patients had an A1c ≥9%. These findings indicate that a sizeable percentage of T2D cases are not being well controlled, and this phenomenon appears to be exacerbated in patients with higher BMIs. There were notable trends in the current dataset showing increasing rates of poor glycaemic control with increasing BMI category. The opposite was also apparent, in that the highest proportion of patients with good glycaemic control (A1c <7%) was noted in the lowest BMI category and was lower in each subsequent increase in BMI status. Mean A1c in this study was 7.2% in non-obese patients with T2D, and increased slightly to 7.5% in the highest 2 BMI categories. NHANES data showed similar mean A1c values ranging from 7.0% to 7.2% in obese BMI categories.

It should be noted that these data do not provide any means to evaluate cause and effect relationships or explain all the findings. The data suggest that patients with T2D and higher BMI may be more difficult to treat than those with lower BMI, as weight loss has been correlated with improved glycaemic control.20–27 Alternatively, patients with more poorly controlled T2D may, as a result, have higher BMIs. There are likely a complex variety of factors at play across the entire population, and even within individual patients.

Current guidelines from the ADA and the EASD suggest lifestyle modification (diet, exercise and weight reduction) as the initial approach to T2D.7 If lifestyle modification does not achieve the desired A1c target within about 3 months (A1c <7%), pharmacological therapy should be initiated, which includes oral antidiabetic agents and/or insulin.7 Given the progressive nature of the disease, a great majority of patients eventually require insulin.28,29 In the current study, insulin user groups had the highest proportions of patients with poor A1c control compared with other medication class users. Regardless of BMI, about half of insulin users had an A1c ≥8%. This could reflect more aggressive prescribing for patients who already had poorly controlled disease, or suggestive evidence that such regimens were not overly effective in many
patients. In addition, obesity itself is associated with insulin resistance. The current data were not longitudinal and not designed to capture length of therapy which might provide more insight for interpretation of the A1c findings in relationship to treatment type. In addition, the general category of ‘insulin’ used in this study did not distinguish specific regimens such as basal, bolus, or a combination of both.

An evaluation of comorbidity prevalence between BMI categories in this population of patients with T2D suggested little difference between BMI groups for comorbidities commonly associated with T2D. In fact, the prevalence of several comorbidities (cardiovascular, nephropathy, peripheral vascular disease and cerebrovascular) showed a slight trend of decreasing as BMI increased, and mean DCSI score was lower in each sequentially higher BMI category. The one exception was hypertension which increased in prevalence as BMI increased, possibly a factor of higher BMI placing greater demands on the cardiovascular system despite the absence of overt cardiovascular disease, peripheral vascular disease or cerebrovascular disease. One potentially confounding issue is that age and BMI had an inverse relationship in this study, with higher BMI groups having lower mean ages. In general, the incidence of comorbidities would be expected to increase with age, even while BMI may be decreasing. However, given the younger mean ages in the higher BMI groups, those patients may have had a more recent T2D diagnosis, thus lower rates of comorbidities, which otherwise tend to be associated with disease duration. These findings are even more perplexing in light of the observation that higher BMI groups demonstrated less effective glycaemic control relative to lower BMI groups.

This study has certain inherent limitations based on design. Despite the sheer size of the patient population and the presumed reliability of data obtained from an EMR database, such data represent a cross-sectional snapshot of clinical and treatment characteristics and patterns. While the Quintiles EMR database is large and includes patients from 49 US states, the patient population may not be completely representative of the general T2D population in the USA or the world.

In conclusion, the current data indicate that roughly one out of four patients with T2D is not well controlled, and the prevalence of poor glycaemic control increases as BMI increases. These findings are sobering in light of the burgeoning diabetes epidemic and ongoing evolution of treatment strategies and new treatment options. Continued efforts need to be directed toward aggressive intervention, particularly in obese patients with T2D who, for possibly a variety of reasons, may be particularly difficult to manage.

Contributors WW, YT, TMH, SXK, BS, and JB were involved in study concept and design. YT conducted data collection. WW, YT, and ESK were involved in data analysis and interpretation. WW and EK contributed to the outline and first draft of the manuscript. WW, YT, ESX, TMH, SXK, BS, and JB all critically revised the manuscript at each stage and provided final approval of the manuscript.

Funding This study was funded by Novo Nordisk (Plainsboro, New Jersey). The authors received writing and editorial assistance from Judith Adams, PharmD and Sandra Westra, PharmD (Churchill Communications, Maplewood, New Jersey, USA) with funding from Novo Nordisk.

Competing interests WW and TMH are employees and stockholders of Novo Nordisk. SXK is an employee of Novo Nordisk. JB, EK, BS and YT were employees of Novo Nordisk at the time the study was performed.

Provenance and peer review Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

REFERENCES

1. West KM. Epidemiology of Diabetes and its vascular lesions. New York: Elsevier North-Holland, 1978:234–48.
2. Barrett-Connor E. Epidemiology, obesity, and non-insulin-dependent diabetes mellitus. Epidemiol Rev 1989;11:172–81.
3. Sluik D, Boeing H, Montonen J, et al. Associations between general and abdominal adiposity and mortality in individuals with diabetes mellitus. Am J Epidemiol 2011;174:22–34.
4. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study, BMJ 2000;321:405–12.
5. Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American association of clinical endocrinologists and american college of endocrinology on the comprehensive type 2 diabetes management algorithm-2016 executive summary. Endocr Pract 2016;22:84–113.
6. Gallo M, Mannucci E, De Cosmo S, et al. Algorithms for personalized therapy of type 2 diabetes: results of a web-based international survey. BMJ Open Diabetes Res Care 2015;3:e000109.
7. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364–79.
8. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American diabetes association and the European association for the study of diabetes. Diabetes Care 2015;38:140–9.
9. National Institute for Health and Care Excellence Guidance. Type 2 diabetes in adults: management. https://www.nice.org.uk/guidance/ng28 (accessed 1 Dec 2016).
10. Higgins V, Piery J, Roughley A, et al. Trends in medication use in patients with type 2 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015. Diabetes Metab Syndr Obes 2016;9:371–80.
11. Young BA, Lin E, Von Korff M, et al. Diabetes complications severity index and risk of mortality, hospitalization, and healthcare utilization. Am J Manag Care 2008;14:15–23.
12. National Heart, Lung, and Blood Institute. The practical guide: identification, evaluation, and treatment of overweight and obesity in adults, 2000. NIH Publication No. 00-4084.
13. Crawford AG, Cote C, Couto J, et al. Comparison of GE Centricity Electronic Medical Record database and National Ambulatory Medical Care Survey findings on the prevalence of major conditions in the United States. Popul Health Manag 2010;13:139–50.
14. Ashton V, Zhang Q, Zhang NJ, et al. LDL-C levels in US patients at high cardiovascular risk receiving rosuvastatin monotherapy. Clin Ther 2014;36:792–9.
15. Hansen RA, Farley JF, Maciejewski ML, et al. Real-world utilization patterns and outcomes of colesevelam HCL in the GE electronic medical record. BMC Endocr Disord 2013;13:24.
16. Holt TA, Gunnarsson CL, Cloud PA, et al. Identification of undiagnosed diabetes and quality of diabetes care in the United

BMJ Open Diab Res Care 2017;5 e000382. doi:10.1136/bmjdrdc-2016-000382 7
Obesity Studies

States: cross-sectional study of 11.5 million primary care electronic records. CMAJ Open 2014;2:E248–55.

17. Brixner D, Ghate SR, McAdam-Marx C, et al. Association between cardiometabolic risk factors and body mass index based on diagnosis and treatment codes in an electronic medical record database. J Manag Care Pharm 2008;14:756–67.

18. Brixner DI, Bron M, Bellows BK, et al. Evaluation of cardiovascular risk factors, events, and costs across four BMI categories. Obesity 2013;21:1284–92.

19. Mocarski M, Tian Y, Smolarz G, et al. Use of ICD-9 codes for obesity: trends in the United States form an electronic health record-derived database. [paper in submission OR poster].

20. Flegal KM, Carroll MD, Kit BK, et al. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 2012;307:483–90.

21. Ogden CL, Carroll MD, Kit BK, et al. Prevalence of obesity and trends in body mass index among US children and adolescents, 1999-2010. JAMA 2012;307:483–90.

22. Albers JW, Herman WH, Pop-Busui R, et al. Effect of prior intensive insulin treatment during the diabetes control and complications trial (DCCT) on peripheral neuropathy in type 1 diabetes during the epidemiology of diabetes interventions and complications (EDIC) Study. Diabetes Care 2010;33:1090–6.

23. American Diabetes Association. (8) Glycemic targets. Diabetes Care 2015;38:S33–40.

24. Nguyen NT, Nguyen XM, Lane J, et al. Relationship between obesity and diabetes in a US adult population: findings from the National Health and Nutrition Examination Survey, 1999-2006. Obes Surg 2011;21:351–5.

25. Aucott LS, Philip S, Avenell A, et al. Patterns of weight change after the diagnosis of type 2 diabetes in Scotland and their relationship with glycaemic control, mortality and cardiovascular outcomes: a retrospective cohort study. BMJ Open 2016;6:e010836.

26. Wing RR. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the look AHEAD trial. Arch Intern Med 2010;170:1566–75.

27. Feldstein AC, Nichols GA, Smith DH, et al. Weight change in diabetes and glycemic and blood pressure control. Diabetes Care 2008;31:1960–6.

28. Liebl A, Prager R, Binz K, et al. Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial. Diabetes Obes Metab 2009;11:45–52.

29. Abrahamson MJ, Peters A. Intensification of insulin therapy in patients with type 2 diabetes mellitus: an algorithm for basal-bolus therapy. Ann Med 2012;44:836–46.

30. Ye J. Mechanisms of insulin resistance in obesity. Front Med 2013;7:14–24.